Selective Internal Radiation Therapy and 188Re-SSS Lipiodol Treatment for Liver Cancer (Lip-Re2)

The goal of this monocentric interventional study is to evaluate the efficacy, in terms of objective response rate, of the 188Re-SSS lipiodol SIRT in patients with non-operable HCC.

Inclusion Criteria: * Age ≥ 18 * ECOG Performance Status 0-1 * HCC with histological diagnosis or non-invasive diagnosis according to AASLD criteria * Non operable and not accessible to ablation therapy * At least one measurable lesion using mRECIST * Tumor involvement \ 6 UNL 6. Creatinine \> 1,5 UNL 7. TSH \< 0,2 µUI/L * Chronic respiratory insufficiency history * Known hemophilia with exophytic tumor \> 1 cm * Extra-hepatic metastasis except hilum node \< 2 cm * Lung shunt \>20% evaluated with 99mTc albumin macroaggregate (MAA) * Poor tumor targeting with 99mTc albumin macroaggregate (MAA) * Previous SIRT * Previous systemic treatment within 4 weeks before radioembolization * More than 2 previous TACE (or embolization), in the area to be treated * Other neoplasia except if complete remission from at least one year * Contraindication related to the technique, in particular severe arterial pathology of the lower limbs or the aorta contraindicating or making difficult an arteriography by femoral approach * Pregnant woman or likely to be or breastfeeding, or male or female patients of reproductive potential without effective contraception from screening to 1 month after the end of the treatment * Minors, individual deprived of liberty, or under any kind of guardianship or trusteeship. * Patients unable to submit to medical follow-up of the study for social, medical or psychological reasons.